A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Phnegative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly-Diagnosed Older Adults or Adults With Relapsed or Refractory Disease and Feasibility Study of Ponatinib With Inotuzumab Ozogamicin Followed By Ponatinib With Blinatumomab for Ph-Positive CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia